CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. 

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 03, 2019

News & Publications

previousnext
Inference of patient-specific evolutionary dynamics and the timing of metastasis from cancer genomic data using SCIMET.
CTD²
July 01, 2019

Both the timing and molecular determinants of metastasis are unknown, hindering treatment and prevention efforts. Here we characterize the evolutionary dynamics of this lethal process by analyzing exome-sequencing data from 118 biopsies from 23 patients with colorectal cancer with metastases to...

Summary hypothesis of the effects of SOX4 on WNT5a and invasion.
CTD²
June 26, 2019

Sry‑Related HMG‑BOX‑4 (SOX4) is a developmental transcription factor that is overexpressed in as many as 23% of bladder cancer patients; however, the role of SOX4 in bladder cancer tumorigenesis is not yet well understood. Given the many roles of SOX4 in embryonic development and the context‑...

Data analysis framework embedded with nested stratified repeated cross-validation
CTD²
June 26, 2019

Background: Radiomics-based non-invasive biomarkers are promising to facilitate the translation of therapeutically related molecular subtypes for treatment allocation of patients with head and neck squamous cell carcinoma (HNSCC).

Methods: We included 113...

Graphical abstract from Huang, et al (2019).
CTD²
June 11, 2019

Human neural stem cell cultures provide progenitor cells that are potential cells of origin for brain cancers. However, the extent to which genetic predisposition to tumor formation can be faithfully captured in stem cell lines is uncertain. Here, we evaluated neuroepithelial stem (NES) cells,...

Graphical abstract from Yong, et al (2019).
CTD²
June 10, 2019

We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitorsinduces replication stress, DNA damage, and abrogates the G2 DNA damage...

O
O
O
O
O